• Discounts and special offers
  • Subscriber-only articles and interviews
  • Breaking news and trending topics

Already a subscriber?

By signing up, you accept Moneywise's Terms of Use, Subscription Agreement, and Privacy Policy.

Not interested ?

Top Stories
A woman injecting dose of Ozempic Peter Dazeley/Getty Images

1 in 8 Americans now take GLP-1 drugs — UPS is investing $48 million to keep them cold

As demand for GLP-1 drugs grows, logistics companies are investing in temperature-controlled facilities to keep the medications moving safely through the supply chain.

To keep pace, United Parcel Service (UPS) is investing $48 million to expand its global healthcare logistics network, according to an exclusive CNBC report.

Advertisement

The company is adding 27 cold-chain facilities across the Americas, Europe and Asia to transport medicines that require strict refrigeration. UPS said the expansion will help move sensitive pharmaceutical products more quickly while strengthening visibility and oversight throughout the delivery process.

Read the best of Moneywise in 5 minutes or less.

By signing up, you accept Moneywise Terms of Use, Subscription Agreement, and Privacy Policy.

In a statement to Moneywise, a UPS spokesperson said newer therapies are changing how medications are transported and handled.

“We’re seeing a clear shift in healthcare toward treatments that are more specialized, sensitive and less forgiving to move particularly biologics and the boom in newer therapies like GLP‑1s that need to stay within a specific temperature range the entire time,” the spokesperson said in an email.

Demand is rising

The investment comes as demand for temperature-sensitive medicines continues to grow. Research firm Growth Market Reports projects the market for temperature-sensitive biologics will grow at an 8.3% compound annual rate through 2033, driven in part by the rapid adoption of GLP-1 medications.

One factor behind that growth is the rapid adoption of GLP-1 medications. Nearly one in eight U.S. adults have taken a GLP-1 drug, according to a 2025 KFF poll.

At the same time, prescriptions for obesity-related GLP-1 drugs surged nearly 587% between 2019 and 2024, according to FAIR Health, while analysts expect the global market for the medications to approach $200 billion by 2030.

Medications like Novo Nordisk’s Wegovy and Ozempic have to stay refrigerated while they’re transported to remain effective, making dependable cold-chain shipping more important than ever.

The need goes beyond weight-loss drugs. The World Health Organization estimates that roughly half of all vaccines are wasted each year, in part because of failures in temperature-controlled storage and transportation.

Must Read

Join 250,000+ readers and get Moneywise’s best stories and exclusive interviews first — clear insights curated and delivered weekly. Subscribe now.

A growing focus on healthcare

UPS said the investment will speed up deliveries while improving tracking and oversight throughout the supply chain.

According to the spokesperson, the new cross-dock facilities are designed to improve handling when shipments move between different modes of transportation, such as from air to ground, where delays or temperature changes are more likely to occur.

Advertisement

In addition to its temperature-controlled network, UPS operates a 24/7 control tower that monitors shipments in real time, helping identify potential disruptions and coordinate interventions when necessary.

CEO Carol Tomé said during the company’s first-quarter earnings call in April that healthcare has become one of UPS’s fastest-growing businesses.

“Our global healthcare portfolio has gained market share every year since 2021,” she said on the call. “And in the first quarter of this year, we generated our first $3 billion healthcare revenue quarter ever, with all three of our segments delivering year-over-year revenue growth.”

As biologic drugs become more common, UPS is betting the infrastructure needed to move them safely will become an increasingly valuable part of its business.

You May Also Like

Share this:
Victoria Vesovski Staff Reporter

Victoria Vesovski is a Toronto-based staff reporter at Moneywise covering personal finance, lifestyle and trending news. She holds degrees from the University of Toronto and New York University, and her work has appeared on platforms including Yahoo Finance, MSN Money and Apple News.

more from Victoria Vesovski

Explore the latest

Disclaimer

The content provided on Moneywise is information to help users become financially literate. It is neither investment, tax nor legal advice, is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities, enter into any loan, mortgage or insurance agreements or to adopt any investment strategy. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional. We make no representation or warranty of any kind, either express or implied, with respect to the data provided, the timeliness thereof, the results to be obtained by the use thereof or any other matter. Advertisers are not responsible for the content of this site, including any editorials or reviews that may appear on this site. For complete and current information on any advertiser product, please visit their website.

†Terms and Conditions apply.

Sign up free.

Join 250,000+ readers by activating your free account. Get our newsletter, a Warren Buffett investing guide, and commenting access on stories.

By signing up, you accept Moneywise Terms of Use, Subscription Agreement, and Privacy Policy.

Already signed up?